Liquidia jumps 26.6% after settlement secures YUTREPIA commercialization

What happened

Liquidia (LQDA) rose 26.6% on October 14, 2026, after a global settlement with United Therapeutics secured continued commercialization of YUTREPIA in exchange for $380.7 million in payments. The company said the agreement resolves all pending litigation over the inhaled treprostinil for pulmonary arterial hypertension, according to Barrons and GlobeNewsWire. The move came as the S&P 500 fell 1.1% and the healthcare sector median fell 0.8% on the day. Trading was heavy: the session traded 3.8 times its 20-day average, and the stock opened 33.2% above the previous close.

How big was the move

This was a substantial, mostly company-specific move: the stock moved far more than the market and its sector. The change was 2.2 times a typical daily move for this stock and 27.4 percentage points better than the sector median. Over the last five sessions Liquidia rose 27.2% while the S&P 500 over five sessions fell 1.1%, underscoring how the settlement stood out against a weak market. Market sensitivity remains elevated, with a beta of 1.53, meaning the stock tends to move more than the market.

The technical picture

Technical indicators paint a mixed picture. The stock is 27.2% below its 20-day moving average, 45.9% below its 50-day moving average and 37.1% below its 200-day moving average. The 50-day average is above the 200-day average, a sign of an established uptrend despite the stock trading below those averages. Momentum is neutral: a Relative Strength Index (14 days) of 35 sits in the 30-to-70 range. Volatility is elevated at 190% annualized over 60 days, the highest reading of the past five years. Recent price history shows a sharp decline over shorter horizons—change over one month fell 48.4% and change over three months fell 54.9%—even as the stock rose 42.8% over one year, 26.8 percentage points ahead of the S&P 500. The stock sits 63.7% below the 52-week high.

Fundamentals and valuation

On a trailing four-quarter basis through June 30, 2026, Liquidia reported revenue of $450.9 million, which grew 2233.6% from a year earlier and showed growth of 1936.7% versus one quarter earlier. Diluted earnings per share for that period were $1.37. Gross margin widened to 92.5% from 70.4% a year earlier. Operating margin was 37.4% compared with 715.4% a year earlier. Free-cash-flow margin was 13.4% and return on invested capital was 46.9%. The balance sheet shows net cash of $155.2 million.

Valuation measures offer a contrasting view. The stock traded at 24.8 times trailing earnings and 13.7 times expected earnings, with a free-cash-flow yield of 2.5%. Share count over one year increased by 18.5%, which can dilute per-share metrics even as revenue expands rapidly. PromtFinance scores rank the company highly for Growth at 99 and for Revisions at 97, while Stability scored 36, indicating uneven near-term predictability.

Earnings and analyst expectations

Liquidia last reported on August 12, 2026, with earnings per share of $0.74 against $0.70 expected, 5.7% above estimates. That marked four consecutive quarters beating estimates and an average surprise over the last four reports of 59.3% above estimates. The typical two-day reaction after recent reports was that the stock rose 3.7%. The next report is scheduled for November 2, 2026.

Analysts are broadly positive. Among seven analysts with ratings, the consensus rating is Buy, with 86% of ratings in the Buy category. The consensus price target is $83.20, 145.1% above the closing price, signalling expectations for substantial upside versus the current market value of $2.43 billion.

What to watch

• November 2, 2026: next scheduled earnings report
• $380.7 million: payment Liquidia will make under the settlement with United Therapeutics
• Trading volume relative to average: the session traded 3.8 times its 20-day average
• Consensus price target: $83.20, 145.1% above the closing price
• Share count over one year: increased by 18.5%